• 1
    Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:33272.
  • 2
    Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;69:659.
  • 3
    Isojärvi JIT, Laatikainen TJ, Pakarinen JA, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:13838.
  • 4
    Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:57984.
  • 5
    Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine and insulin mediated risks in women with epilepsy. Ann Neurol 1998;41:44651.
  • 6
    Raeven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595604.
  • 7
    Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993;39;1–16.
  • 8
    Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:42531.
  • 9
    Halaas JL, Gafiwala KS, Mafei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:5436.
  • 10
    Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:61932.
  • 11
    Smith FJ, Campfield LA, Moschera JA, et al. Feeding inhibition by neuropeptide Y. Nature 1996;382:307.
  • 12
    Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:2925.
  • 13
    Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:98891.
  • 14
    Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:2302.
  • 15
    Commission of Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:38999.
  • 16
    Andersen L, Dinesen B, JØrgensen PN, et al. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:57882.
  • 17
    Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993;46:199204.
  • 18
    Vorum H, Lennart G, Honorè B. Valproate and palmitate binding to serum albumin in valproate treated patients: relation to obesity. Epilepsy Res 1993;16:5564.
  • 19
    Panksepp J, Meeker RB. The role of GABA in the ventromedial hypothalamic regulation of food intake. Brain Res Bull 1980;5:45360.
  • 20
    Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:66670.
  • 21
    Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 1996;45:699701.
  • 22
    Han TS, Van Leer, Seidell JC, et al. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 1995;311:14015.